TABLE 3.

Postprimary GMC of serotype-specific pneumococcal antipolysaccharide IgG in studies 1 to 3

Serotype	GMC (μg/ml) in childrena:
	Receiving PncD/T11			Not receiving PncD/T11 (Study 3 [n = 51])
	Study 1 (n = 59)	Study 2 (n = 64-69)	Study 3 (n = 41-47)
TT conjugates
1	1.72 (1.41-2.11)	4.15 (3.42-5.04)	0.51 (0.41-0.64)	0.08 (0.07-0.10)
4	3.30 (2.49-4.37)	5.23 (4.32-6.35)	1.28 (0.99-1.66)	0.08 (0.06-0.10)
5	1.92 (1.51-2.44)	2.23 (1.78-2.80)	1.22 (0.97-1.54)	0.16 (0.12-0.21)
7F	4.24 (3.56-5.06)	3.65 (3.06-4.35)	1.48 (1.16-1.89)	0.07 (0.06-0.09)
9V	1.55 (1.24-1.94)	1.85 (1.46-2.33)	0.51 (0.39-0.65)	0.14 (0.11-0.19)
19F	5.07 (3.63-7.08)	6.63 (4.99-8.81)	2.81 (2.06-3.83)	0.26 (0.21-0.32)
23F	1.48 (1.05-2.09)	1.82 (1.37-2.42)	0.35 (0.27-0.47)	0.10 (0.08-0.13)
DT conjugates
3	1.58 (1.25-2.00)	2.61 (2.20-3.11)	2.33 (1.83-2.99)	0.13 (0.10-0.17)
6B	1.08 (0.76-1.53)	1.28 (0.91-1.81)	0.70 (0.44-1.12)	0.06 (0.04-0.07)
14	1.86 (1.29-2.69)	2.13 (1.58-2.88)	1.33 (0.92-1.91)	0.27 (0.19-0.37)
18C	0.78 (0.58-1.04)	1.17 (0.95-1.45)	0.84 (0.65-1.08)	0.07 (0.05-0.08)

^aThe 95% CI is given in parentheses. P < 0.001 for all serotypes for the groups that did not receive PncD/T11 compared to each of the three studies in children to whom PncD/T11 was administered; P < 0.001 for serotypes 1, 4, 7F, 9V, 23F in study 3 versus study 1 and versus study 2 in children receiving PncD/T11; P < 0.001 for serotypes 5 and 19F in study 3 versus study 2 in children receiving PncD/T11; P < 0.001 for serotype 1 between study 1 and study 2 in children receiving PncD/T11; 0.001 < P < 0.05 for serotypes 3, 4, and 18C between study 1 and study 2 in children receiving PncD/T11; 0.001 < P < 0.05 for serotypes 5 and 19F between study 1 and study 3 in children receiving PncD/T11; 0.001 < P < 0.05 for serotypes 6B between study 2 and study 3 in children receiving PncD/T11.